The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

T he weight-loss drug Zepbound (tirzepatide) now has another major benefit: on Dec. 20, it became the first drug approved by ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

Notably, Zepbound's main rival, the weight loss drug Wegovy from Novo Nordisk ... The index is used to evaluate the severity ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.